Skip to main content
BGI Genomics Co., Ltd. logo

BGI Genomics Co., Ltd. — Investor Relations & Filings

Ticker · 300676 ISIN · CNE100003449 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 1,655 across all filing types
Latest filing 2022-10-25 Interim / Quarterly Rep…
Country CN China
Listing Shenzhen Stock Exchange 300676

About BGI Genomics Co., Ltd.

https://www.bgi.com

BGI Genomics Co., Ltd. is a leading provider of integrated solutions for precision medicine, specializing in genomic sequencing and proteomic services. The company offers a comprehensive portfolio of clinical diagnostics and research services across various fields, including reproductive health, oncology, and infectious diseases. Key products include non-invasive prenatal testing, hereditary cancer screening, and pathogen identification tools. Leveraging proprietary DNBseq sequencing technology, BGI Genomics provides high-throughput, cost-effective genomic data analysis to healthcare providers, research institutions, and pharmaceutical companies worldwide. The organization focuses on advancing personalized medicine through large-scale genomic research and the development of innovative diagnostic applications, aiming to improve health outcomes by making advanced genetic insights accessible to a global population.

Recent filings

Filing Released Lang Actions
2022年三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "深圳华大基因股份有限公司 2022 年第三季度报告" which translates to "Shenzhen BGI Genomics Co., Ltd. 2022 Third Quarter Report." It contains detailed financial data including income, profit, cash flow, assets, liabilities, shareholder information, and notes on business activities and investments for the third quarter of 2022. The document is about 15,000 characters long and includes comprehensive financial statements and management discussion of quarterly performance. It is not an announcement of a report but the report itself, containing substantive financial data and analysis for a period shorter than a full fiscal year. Therefore, it fits the definition of an Interim / Quarterly Report (IR). 9M 2022
2022-10-25 Chinese
独立董事关于第三届董事会第十二次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from independent directors regarding a board meeting decision about increasing the 2022 annual expected amount for related party transactions. It references compliance with stock exchange listing rules and company bylaws. The content focuses on board-level governance and approval of a specific agenda item related to related party transactions. It is not a full financial report, audit, or earnings release. It is not a notice of voting results but an independent opinion on a board matter. Therefore, it fits best under Board/Management Information (MANG), which covers announcements related to board decisions and management matters.
2022-10-25 Chinese
中信证券股份有限公司关于深圳华大基因股份有限公司增加2022年度日常关联交易预计额度的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed verification opinion from CITIC Securities regarding Shenzhen BGI Genomics Co., Ltd.'s increase in the 2022 annual expected daily related-party transaction quota. It includes detailed descriptions of related-party transactions, amounts, approvals by the board and supervisory committee, independent directors' opinions, and compliance with regulatory rules. The document is not a full annual report or financial statement but a regulatory compliance and verification report related to specific transaction approvals. It is not a simple announcement or a brief notice but a substantive regulatory filing related to corporate governance and transaction oversight. Therefore, it fits best under Regulatory Filings (RNS).
2022-10-25 Chinese
独立董事关于第三届董事会第十二次会议相关事项的事前认可意见
Board/Management Information Classification · 95% confidence The document is a statement from independent directors providing prior approval opinions on a specific agenda item for the company's board meeting, specifically regarding the increase of the 2022 annual daily related-party transaction estimated quota. It references regulatory rules and company bylaws but does not contain financial statements or detailed financial data. The document is a governance-related opinion and approval, not a full report or announcement of voting results. It fits best under Board/Management Information (MANG) as it relates to board meeting matters and director opinions.
2022-10-25 Chinese
第三届董事会第十二次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 12th meeting of the 3rd Board of Directors of Shenzhen BGI Genomics Co., Ltd. It includes details about the meeting date, attendance, voting results, and approval of the 2022 third quarter report and an increase in related party transaction limits. The document does not contain the full third quarter financial report itself but references that the report is disclosed on another platform (cninfo.com.cn). The document is relatively short (1232 characters) and serves as a meeting resolution announcement rather than a full financial report. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of board decisions and management matters.
2022-10-25 Chinese
第三届监事会第十三次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of Shenzhen BGI Genomics Co., Ltd. It details the convening and voting results of the 13th meeting of the 3rd Supervisory Board, including approval of the 2022 Q3 report and an increase in the 2022 daily related-party transaction limit. The document is short (1241 characters) and primarily announces meeting resolutions and approvals rather than containing the full quarterly report or detailed financial data. It also references that the 2022 Q3 report is disclosed on an external website, indicating this document is an announcement of meeting resolutions rather than the report itself. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and meeting resolution notice, not as an Interim/Quarterly Report (IR) or Annual Report (10-K).
2022-10-25 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.